(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Oric Pharmaceuticals's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2026 to be $1,393,669,395, with the lowest ORIC revenue forecast at $212,233,918, and the highest ORIC revenue forecast at $2,575,104,872. On average, 1 Wall Street analysts forecast ORIC's revenue for 2027 to be $11,105,560,861, with the lowest ORIC revenue forecast at $11,105,560,861, and the highest ORIC revenue forecast at $11,105,560,861.
In 2028, ORIC is forecast to generate $29,422,358,626 in revenue, with the lowest revenue forecast at $29,422,358,626 and the highest revenue forecast at $29,422,358,626.